Literature DB >> 2495814

The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis.

A I Mallet1, P Norris, N B Rendell, E Wong, M W Greaves.   

Abstract

Treatment of four mastocytosis patients with the mast cell stabilising drugs, disodium cromoglycate and ketotifen failed to alter significantly the urinary excretion levels of histamine or N tau-methylimidazole acetic acid. No clinical improvement was noted in any subject after treatment by either drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495814      PMCID: PMC1379709          DOI: 10.1111/j.1365-2125.1989.tb05339.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Oral disodium cromoglycate in the treatment of systemic mastocytosis.

Authors:  N A Soter; K F Austen; S I Wasserman
Journal:  N Engl J Med       Date:  1979-08-30       Impact factor: 91.245

2.  Association of platelet-activating factor with primary acquired cold urticaria.

Authors:  K E Grandel; R S Farr; A A Wanderer; T C Eisenstadt; S I Wasserman
Journal:  N Engl J Med       Date:  1985-08-15       Impact factor: 91.245

3.  Prostaglandin D2 and histamine release in cold urticaria.

Authors:  D J Heavey; A Kobza-Black; S E Barrow; C G Chappell; M W Greaves; C T Dollery
Journal:  J Allergy Clin Immunol       Date:  1986-09       Impact factor: 10.793

4.  Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias.

Authors:  D P Huston; R B Bressler; M Kaliner; L K Sowell; M W Baylor
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

5.  Factitious wealing at the site of previous cutaneous response.

Authors:  J James; R P Warin
Journal:  Br J Dermatol       Date:  1969-12       Impact factor: 9.302

6.  Increased production of prostaglandin D2 in patients with systemic mastocytosis.

Authors:  L J Roberts; B J Sweetman; R A Lewis; K F Austen; J A Oates
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

7.  Comparative evaluation of the radioenzymatic method for the determination of urinary histamine with a mass spectrometric assay.

Authors:  L J Roberts; K A Aulsebrook; J A Oates
Journal:  J Chromatogr       Date:  1985-02-27

8.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.

Authors:  L B Schwartz; D D Metcalfe; J S Miller; H Earl; T Sullivan
Journal:  N Engl J Med       Date:  1987-06-25       Impact factor: 91.245

9.  Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial.

Authors:  M Frieri; D W Alling; D D Metcalfe
Journal:  Am J Med       Date:  1985-01       Impact factor: 4.965

10.  Ketotifen: current views on its mechanism of action and their therapeutic implications.

Authors:  L P Craps; U M Ney
Journal:  Respiration       Date:  1984       Impact factor: 3.580

  10 in total
  3 in total

Review 1.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 2.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 3.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.